A feed for the blog https://xitter.cf/t.co/pXYAKACULR. Discusses the covalent modification of proteins. Available on bsky and mass std don
Ottawa, Ontario
Joined April 2017
- Tweets843
- Following310
- Followers4.4K
- Likes66
Covalent Modifiers retweeted
Clinical update for zoldonrasib - Ras(on)G12D selective covalent inhibitor - dosed at 1200 mg qd po (MTD previously not reached). Generally well tolerated, 89% disease control rate for NSCLC patients, two promising case studies shared, but still very early days. #AACR25 @AACR
Covalent Modifiers retweeted
Excited to see the final version of our manuscript out in @CellChemBiol! In this study, we investigate the mechanism of action of an immunosuppressive small-molecule electrophile, which targets a core splicing factor SF3B1! @RockefellerUniv authors.elsevier.com/a/1k9mh…
Covalent Modifiers retweeted
Please vote, and please vote for Kamala Harris and Tim Walz. Wise words from Derek Lowe, In The Pipeline blog:
science.org/content/blog-pos…
Covalent Modifiers retweeted
One of my newest adventures - hosting a podcast!
If you are keen on chemical biology, medicinal chemistry, chemical probes, tool compounds, degraders, chemoproteomic tools, and more... tune to @Target2035 podcasts. Pilot episode is out... more to come!
podcasters.spotify.com/pod/s…
Covalent Modifiers retweeted
We are thrilled to announce that @Keribackus has been promoted to the rank of Associate Professor with tenure! We congratulate Keri on this well-deserved achievement and look forward to her lab continuing to make impactful discoveries! 👏👏🎉🍾
Covalent Modifiers retweeted
Thrilled to have been invited to write this JMC editorial on Covalent inhibitors! @ACSBioMed Enjoy the quick read.
pubs.acs.org/doi/10.1021/acs…
Covalent Modifiers retweeted
Just in: Bristol Myers Squibb's Krazati is now the first KRAS G12C inhibitor to be approved for colorectal cancer.
endpts.com/bristol-myers-win…
Covalent Modifiers retweeted
Congrats to Prof. Benjamin Cravatt for receiving the 2024 Bristol Myers Squibb Award for Enzyme Chemistry from the @ACS_DivBioChem. His work in activity-based protein profiling revolutionizes treatments for neurological disorders and cancer. 🎉🌟 More at: ow.ly/p6KL50RyOwU
Covalent Modifiers retweeted
The three-part New Drugs on the Horizon Series at the AACR Annual Meeting 2024 wrapped up this morning. A total of 12 first-time disclosures were presented.
bit.ly/3J8AmVM
#AACR24
Covalent Modifiers retweeted
Here is the summary from the three „New Drugs on the Horizon“ sessions at #AACR24 once again. What an impressive mix of drug modalities. And for the NCEs it clearly shows that chirality is the rule not the exception. The future of NCE drug discovery is bright and chiral. – at Weiterstadt, Deutschland
The three-part New Drugs on the Horizon Series at the AACR Annual Meeting 2024 wrapped up this morning. A total of 12 first-time disclosures were presented.
bit.ly/3J8AmVM
#AACR24
Covalent Modifiers retweeted
Holy shit! Revolution Medicines’ #KRas G12D inhibitor RMC-9805 covalently labels the oncogenic aspartate with a aziridine warhead making use of 9 (!) stereocenters to achieve potency, selectivity & stability. My thoughts & prayers are with the process chemistry team. #AACR24
Covalent Modifiers retweeted
Congratulations to Ben Cravatt of @scrippsresearch on receiving the 2024 Bristol Myers Squibb Award in Enzyme Chemistry! The Cravatt lab has had substantial impacts ranging from fundamental research to advancing clinical candidates. Hear more during our symposium at #ACSFall2024!
Covalent Modifiers retweeted
Frontier Science: Chemoproteomics w/ Prof. Dan Nomura @UCBerkeley
Prof. @DanNomura is revolutionizing drug discovery! Explore chemoproteomics, targeted protein degradation, & his transition from academia to founding @FrontierMeds.
See our episode below: buff.ly/47YhN0H
Covalent Modifiers retweeted
Naturally Occurring and Widespread Resistance to Bioactive Natural Products (C. Zhang et al.) onlinelibrary.wiley.com/doi/…
Covalent Modifiers retweeted
The Covalent Drug Comeback
Several recent anecdotes in covalent inhibitor drug discovery seem to reflect changing attitudes about covalents, including billion-dollar acquisitions, approvals outside oncology, and notable clinical candidates.
Full article: drughunters.com/3R4kJlW
Covalent Modifiers retweeted
KRAS Roundup: Twelve G12C Clinical Candidates to Know
From sotorasib's regulatory delay, to adagrasib's acquisition by BMS, to divarasib's unexpectedly positive data, to MK-1084's combinability with PD-1, there's so much to watch.
Full article: drughunters.com/3Qbrwty
Covalent Modifiers retweeted
A great three days filled with the top science in ABPP and chemical proteomics #ABPP2023 - also, the perfect opportunity to share our findings on covalent targeting of Rab27!
Covalent Modifiers retweeted
It’s always a tour de force when @DanNomura presents his lab’s work, and his presentation at the @ACS_CVS Frontiers in Organic Chemistry symposium was no exception. So much potential in covalent fragment screening for TPD.
Covalent Modifiers retweeted
I will be hosting a great online seminar Tue Mar 21 at 2 PM ET, featuring Dr. Sang @ualbertachem and Dr. Awoonor-Williams from @Novartis . Register online cheminst.ca/cic-virtual/semi…
Covalent Modifiers retweeted
SCT announces its next webinar "Covalent Molecular Probes" sponsored by Edelris and Covant. Nov. 21st , 4:30pm (CET) with a great program!
Registrations are open:univ-lille-fr.zoom.us/webina…
@EuroMedChem @SCT_YMCF @SCIYoungChem @YoungSciNet
